We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+13.46%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
+$28.4M
Cap. Flow
-$577M
Cap. Flow %
-26.84%
Top 10 Hldgs %
29.86%
Holding
143
New
30
Increased
17
Reduced
35
Closed
30

Top Buys

Rank Stock Value
1
RNA
PROSENSA HLDGS N V ORD SHS (NLD)
RNA
+$75.8M
2
THOR
THORATEC CORPORATION
THOR
+$31.1M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$30.7M
4
VTRS icon
Viatris
VTRS
+$27.4M
5
TRAW icon
Traws Pharma
TRAW
+$24.3M

Top Sells

Rank Stock Value
1
OPTR
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
+$43.8M
2
AUXL
AUXILIUM PHARAMCEUTICALS INC
AUXL
+$42.7M
3
NKTR icon
Nektar Therapeutics
NKTR
+$34M
4
STJ
St Jude Medical
STJ
+$24M
5
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$23.8M

Sector Composition

Rank Sector Weight
1 Healthcare 52.2%
2 Technology 1.35%
3 Financials 1.05%
4 Consumer Discretionary 0%
5 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARAY icon
101
Accuray
ARAY
$30.8M
– –
-1,420,000
Closed -$8.15M
ATRC icon
102
AtriCure
ATRC
$1.77B
– –
-630,000
Closed -$5.99M
BMRN icon
103
BioMarin Pharmaceuticals
BMRN
$11.5B
– –
-247,000
Closed -$13.8M
CYTK icon
104
Cytokinetics
CYTK
$10.9B
– –
-1,779,622
Closed -$20.6M
GILD icon
105
Gilead Sciences
GILD
$167B
– –
-35,000
Closed -$1.79M
HCA icon
106
HCA Healthcare
HCA
$82.3B
– –
-553,020
Closed -$19.9M
HUM icon
107
Humana
HUM
$48B
– –
-188,000
Closed -$15.9M
IART icon
108
Integra LifeSciences
IART
$1.5B
– –
-631,297
Closed -$9.45M
ILMN icon
109
Illumina
ILMN
$28.2B
– –
-8,634
Closed -$629K
MYGN icon
110
Myriad Genetics
MYGN
$584M
– –
-18,777
Closed -$505K
NKTR icon
111
Nektar Therapeutics
NKTR
$2.31B
– –
-195,983
Closed -$34M
MDRX
112
DELISTED
Veradigm Inc. Common Stock
MDRX
– –
-619,360
Closed -$8.02M
SGEN
113
PUT
DELISTED
Seagen Inc. Common Stock
SGEN
– –
-300,000
Closed -$9.44M
RAD
114
DELISTED
Rite Aid Corporation
RAD
– –
-35,000
Closed -$2M
LHCG
115
DELISTED
LHC Group LLC
LHCG
– –
-19,087
Closed -$374K
CLVS
116
DELISTED
Clovis Oncology, Inc.
CLVS
– –
-306,018
Closed -$20.5M
VCRA
117
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
– –
-273,858
Closed -$4.03M
TTPH
118
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
-27,745
Closed -$3.9M
ACHN
119
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-1,629,833
Closed -$13.3M
STJ
120
DELISTED
St Jude Medical
STJ
– –
-525,000
Closed -$24M
HTWR
121
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-225,167
Closed -$21.4M
CTRX
122
CALL
DELISTED
CATAMARAN CORP COM STK (CDA)
CTRX
– –
-550,000
Closed -$26.8M
GTIV
123
DELISTED
GENTIVA HEALTH SERVICES INC
GTIV
– –
-77,839
Closed -$775K
OPTR
124
DELISTED
OPTIMER PHARMACEUTICALS, INC. COM STK
OPTR
– –
-3,025,829
Closed -$43.8M
WCRX
125
DELISTED
WARNER CHILCOTT PLC ORD SHS CL A (IRL)
WCRX
– –
-34,543
Closed -$688K
2 3 4
5
6

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2013 Portfolio in Review

As of Q3 2013, Deerfield Management held 143 positions worth $2.15B, up 1.3% from $2.12B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Deerfield Management withdrew a net $577M in Q3 2013, closing 30 positions and reducing 35 holdings. Its most notable exit was OPTIMER PHARMACEUTICALS, INC. COM STK, an estimated $43.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, up from 51% a quarter earlier, followed by Technology and Financials.

Against the trend, Deerfield Management opened a new position in PROSENSA HLDGS N V ORD SHS (NLD) worth $21.3M.

  • Deerfield Management's largest Q3 2013 buy was PROSENSA HLDGS N V ORD SHS (NLD): 3,224,524 shares worth $21.3M.
  • Deerfield Management added most to Spectrum Pharmaceuticals Inc in Q3 2013, an estimated $24.3M increase.
  • Deerfield Management's biggest Q3 2013 reduction was AUXILIUM PHARAMCEUTICALS INC, cutting an estimated $42.7M.
  • Deerfield Management fully exited OPTIMER PHARMACEUTICALS, INC. COM STK in Q3 2013, selling an estimated $43.8M.
  • Deerfield Management's ten largest holdings make up 30% of its $2.15B portfolio in Q3 2013.
  • Deerfield Management opened 30 new positions and closed 30 in Q3 2013.
  • Deerfield Management's portfolio value rose 1.3% quarter-over-quarter to $2.15B.

Based on Deerfield Management's 13F filing for Q3 2013, filed 14 Nov 2013.